Navigation Links
Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:4/1/2008

ttee on Resuscitation (ILCOR) have issued guidelines recommending that cardiac arrest victims be treated with induced hypothermia.

Ischemic diseases constitute the largest segment of the medical market in the United States and in almost all developed countries worldwide. For example, in the U.S. and other developed countries, an estimated 1.4 million people experience cardiac arrest each year, of which an increasing number (currently about 350,000) survive to receive advanced care. The AHA guidelines now recommend the use of therapeutic cooling as part of the critical care procedures for patients with an out-of-hospital cardiac arrest following ventricular fibrillation. With respect to heart attacks, an estimated 325,000 people in the U.S., and approximately 375,000 people outside the U.S., receive emergency angioplasty or anti-clotting treatment as first-line care. Cardium and InnerCool recently announced positive preclinical effects of hypothermia following heart attack and announced a clinical study being co-sponsored by a leading cardiology center in Sweden.

In the area of stroke, approximately 700,000 Americans experience a stroke each year, and a comparable number of patients are affected outside the U.S. Although tissue plasminogen activator (tPA) has been shown to lessen damage associated with a stroke, particularly if it can be administered within three hours of onset, many stroke patients continue to suffer advanced neurologic damage even though they have received tPA. More importantly, most stroke victims do not arrive at the hospital in time to be candidates for tPA. The American Stroke Association (ASA) has now identified the use of therapeutic hypothermia as a promising area of research for the potential treatment of stroke victims, and it is the subject of ongoing clinical studies being sponsored by InnerCool Therapies and supported by the U.S. National Institutes of Health.

For fever control, surface cooling devices are becoming
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
2. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
3. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
4. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
5. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
6. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
7. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
8. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
9. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
10. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
11. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015  The Paul G. Allen Family Foundation announced ... to six groups of researchers with projects at the ... neuroscience: growing mature human brain cells in the laboratory. ... million over three years.  "This new ... especially significant because the field of neuronal maturation is ...
(Date:4/30/2015)... 2015 Available in select spas ... , Fleur’s introduces CC CRÈME ... benefits of makeup, skin care and solar protection ... is designed with specific complexion-correcting pigments to instantly ... and a healthy glow. Far more than a ...
(Date:4/29/2015)... According to a new market ... (Portable & Non-Portable), Component (Accelerometer, Proximity Probe, & ... & Mining, & Others), & Geography - Global ... to reach $1,453.76 Million by 2020, at a ... tables and 92 figures spread through 205 pages ...
(Date:4/29/2015)... AlloSource ®, one of the ... and soft-tissue allografts for use in surgical procedures ... the launch of AlloSkin™ AC, an acellular dermal ... (CMS) also moved AlloSkin™ RT, a meshed human ... category for reimbursement. "AlloSource is committed ...
Breaking Biology Technology:The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4AlloSource Announces New Possibilities In Wound Care 2
... EMERYVILLE, Calif., Jan. 3, 2012  Bionovo, Inc. (NASDAQ: ... discovery and development of safe and effective treatments for ... entered into a $5 million securities purchase agreement with ... Socius Capital Group, LLC. (Logo: ...
... Jan. 3, 2012 Dear NeoStem Shareholders, ... back at 2011 - a transformative year for NeoStem (NYSE Amex: ... term catalysts that we expect to move the company forward in ... Progenitor Cell Therapy, LLC ("PCT") and Amorcyte, LLC ("Amorcyte"). , ...
... NEW YORK, Jan. 3, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0203539/Cytogenetics---technologiesmarkets-and-companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics ... cytogenetics in a broader sense rather than ...
Cached Biology Technology:Bionovo Announces $5 Million Financing 2Bionovo Announces $5 Million Financing 3Bionovo Announces $5 Million Financing 4NeoStem's CEO Letter to Shareholders 2NeoStem's CEO Letter to Shareholders 3NeoStem's CEO Letter to Shareholders 4Cytogenetics - Technologies, Markets and Companies 2Cytogenetics - Technologies, Markets and Companies 3Cytogenetics - Technologies, Markets and Companies 4Cytogenetics - Technologies, Markets and Companies 5Cytogenetics - Technologies, Markets and Companies 6Cytogenetics - Technologies, Markets and Companies 7Cytogenetics - Technologies, Markets and Companies 8Cytogenetics - Technologies, Markets and Companies 9Cytogenetics - Technologies, Markets and Companies 10Cytogenetics - Technologies, Markets and Companies 11
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Lolle and colleagues from Purdue University published a paper in ... do not obey the laws of Mendelian inheritance (the idea ... found that these plants were demonstrating genetic traits from older ... of how genes are passed on. At the ...
... Bethesda, MD The Federation of American Societies ... registration for the Science Research Conference (SRC): Mechanism ... 2013 FASEB Science Research Conference on Mechanism and ... 23 in Saxton Rivers, VT. The "Vermont Transcription ...
... mid-nineteenth century, maps have helped elucidate the deadly mysteries ... global mapping of infectious diseases is considerably unreliable and ... outbreaks, according to a new systematic mapping review of ... the 355 infectious diseases assessed in the review, 174 ...
Cached Biology News:Defying the laws of Mendelian inheritance 2Avoiding a cartography catastrophe 2
Request Info...
...
... to Atrophin 1 ( Abpromise for ... Synthetic peptide conjugated to KLH derived ... of Human Atrophin 1.(Note: the amino acid ... .) Entrez GeneID: ...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: